ANI Pharmaceuticals (NASDAQ:ANIP) Posts Earnings Results

ANI Pharmaceuticals (NASDAQ:ANIP) posted its quarterly earnings results on Friday. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.09 by $0.25, Briefing.com reports. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The firm had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. During the same quarter last year, the firm earned $1.05 earnings per share. The business’s revenue for the quarter was up 12.5% on a year-over-year basis. ANI Pharmaceuticals updated its FY 2024 guidance to 4.900-5.050 EPS and its FY24 guidance to $4.90-5.05 EPS.

ANI Pharmaceuticals Trading Up 0.5 %

Shares of ANIP stock traded up $0.30 on Monday, hitting $61.74. The stock had a trading volume of 324,743 shares, compared to its average volume of 216,177. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. The firm has a market capitalization of $1.30 billion, a P/E ratio of -112.25 and a beta of 0.71. ANI Pharmaceuticals has a 1 year low of $48.20 and a 1 year high of $70.81. The company’s 50 day moving average price is $58.61 and its 200-day moving average price is $61.47.

Wall Street Analyst Weigh In

ANIP has been the subject of several recent research reports. Piper Sandler initiated coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday. Truist Financial increased their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. Raymond James increased their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Finally, StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $77.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.